Avid Bioservices Inc (CDMO)

Currency in USD
12.49
0.00(0.00%)
Closed·
Showing Avid Bioservices historical data. For real-time data please try another search
Fair Value
Day's Range
12.4712.51
52 wk Range
5.9812.51
Key Statistics
Prev. Close
12.49
Open
12.49
Day's Range
12.47-12.51
52 wk Range
5.98-12.51
Volume
-
Average Volume (3m)
1.61M
1-Year Change
16.08%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CDMO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Avid Bioservices Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Avid Bioservices Inc Company Profile

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California. As of February 5, 2025, Avid Bioservices, Inc. was taken private.

Employees
371

Avid Bioservices Inc SWOT Analysis


Private Equity Pivot
Explore Avid Bioservices' transition to private ownership, valued at $1.1 billion, and its potential impact on the company's growth trajectory and market position
Gene Therapy Frontie
Delve into Avid's expanding capabilities in gene therapy manufacturing, a promising growth area that could reshape the company's future in biopharmaceuticals
Financial Crossroads
Uncover the complexities of Avid's financial performance, balancing revenue growth with profitability challenges and a FY2025 revenue guidance of $160-168 million
Market Valuation
Analyst price targets range from $8 to $12.50, reflecting varied perspectives on Avid's potential in the competitive CDMO landscape
Read full SWOT analysis

Avid Bioservices Inc Earnings Call Summary for Q1/2025

  • Revenue up 6% to $40.2M; gross profit margin improved to 14%, but net loss widened to $5.5M due to higher SG&A expenses
  • Record backlog of $219M from new project agreements; CEO optimistic about growth prospects despite challenges in cell and gene therapy sector
  • Company expects 40-60% increase in incremental revenue and improved margins; aims to fill remaining capacity to drive growth
  • Relationship with key customer Halozyme remains strong despite revenue decline; focus on diversifying client base
  • BIOSECURE Act may impact half of current pipeline from China; upcoming quarter includes facility maintenance shutdown
Last Updated: 10/09/2024, 13:00
Read Full Transcript

Earnings

Latest Release
Jun 25, 2025
EPS / Forecast
-- / -0.0267
Revenue / Forecast
-- / 47.44M
EPS Revisions
Last 90 days

CDMO Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.